Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

Similar articles for PubMed (Select 11008922)

1.

Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study.

Cartmel B, Moon TE, Levine N, Rodney S, Alberts D.

Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):999-1002.

2.

The effects of an open design on trial participant recruitment, compliance and retention--a randomized controlled trial comparison with a blinded, placebo-controlled design.

Avenell A, Grant AM, McGee M, McPherson G, Campbell MK, McGee MA; RECORD Trial Management Group.

Clin Trials. 2004;1(6):490-8.

PMID:
16279289
3.

Predictors of participant retention in two chemoprevention feasibility trials.

Bowen DJ, Cartmel B, Barnett M, Goodman G, Omenn GS.

Ann Behav Med. 1999 Summer;21(3):210-5.

PMID:
10626026
6.

Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.

Lam S, Xu X, Parker-Klein H, Le Riche JC, Macaulay C, Guillaud M, Coldman A, Gazdar A, Lotan R.

Int J Oncol. 2003 Dec;23(6):1607-13.

PMID:
14612933
7.

Predicting compliance in a breast cancer prevention trial.

Maurice A, Howell A, Evans DG, O'Neil AC, Scobie S.

Breast J. 2006 Sep-Oct;12(5):446-50.

PMID:
16958964
8.

Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin.

Alberts D, Ranger-Moore J, Einspahr J, Saboda K, Bozzo P, Liu Y, Xu XC, Lotan R, Warneke J, Salasche S, Stratton S, Levine N, Goldman R, Islas M, Duckett L, Thompson D, Bartels P, Foote J.

Clin Cancer Res. 2004 Mar 15;10(6):1875-80. Erratum in: Clin Cancer Res. 2004 Aug 15;10(16):5640.

9.

Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757].

Vorobjov S, Hovi SL, Veerus P, Pisarev H, Rahu M, Hemminki E.

Maturitas. 2005 Nov-Dec;52(3-4):286-95. Epub 2005 Aug 1.

PMID:
16055284
10.

Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer.

Hess LM, Saboda K, Malone DC, Salasche S, Warneke J, Alberts DS.

Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2579-83.

11.

Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial.

Röder E, Berger MY, de Groot H, Gerth van Wijk R.

Clin Exp Allergy. 2008 Oct;38(10):1659-67. doi: 10.1111/j.1365-2222.2008.03060.x. Epub 2008 Jul 2.

PMID:
18631346
12.

Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population.

Plummer M, Vivas J, Lopez G, Bravo JC, Peraza S, Carillo E, Cano E, Castro D, Andrade O, Sánchez V, Garcia R, Buiatti E, Aebischer C, Franceschi S, Oliver W, Muñoz N.

J Natl Cancer Inst. 2007 Jan 17;99(2):137-46.

13.

Patient participation and compliance in cancer chemoprevention trials: issues and concerns.

Tangrea JA.

Proc Soc Exp Biol Med. 1997 Nov;216(2):260-5. Review.

PMID:
9349695
14.

Predictors of participant adherence and retention in the African American Study of Kidney Disease and Hypertension.

Brooks D, Charleston J, Dowie D, Gabriel A, Hall YB, Hiremath L, Lightfoot T, Sika M, Smith WC, Wang X.

Nephrol Nurs J. 2008 Mar-Apr;35(2):133-42.

PMID:
18472682
15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.

Effects of long-term intake of retinol on selected clinical and laboratory indexes.

Cartmel B, Moon TE, Levine N.

Am J Clin Nutr. 1999 May;69(5):937-43.

17.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

18.

Chemoprevention of bladder cancer.

Kamat AM, Lamm DL.

Urol Clin North Am. 2002 Feb;29(1):157-68. Review.

PMID:
12109342
19.

Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.

Sample DA, Sinicrope PS, Wargovich MJ, Sinicrope FA.

Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):281-5.

20.

Patients' perceptions on participation in a cancer chemoprevention trial.

Tangrea JA, Adrianza ME, Helsel WE.

Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):325-30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk